Leflunomide in clinical practice
Treatment of rheumatoid arthritis (RA) patients is based on conventional background therapy. This therapy remains the method of choice for patients who had not received basic anti-inflammatory drugs (BAIDs) and is regarded as an obligatory component of combination therapy. The choice of synthetic BA...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
IMA-PRESS LLC
2014-03-01
|
| Series: | Современная ревматология |
| Subjects: | |
| Online Access: | https://mrj.ima-press.net/mrj/article/view/512 |
| Summary: | Treatment of rheumatoid arthritis (RA) patients is based on conventional background therapy. This therapy remains the method of choice for patients who had not received basic anti-inflammatory drugs (BAIDs) and is regarded as an obligatory component of combination therapy. The choice of synthetic BAIDs is relatively small; leflunomide (LEF) is now one of the most promising BAIDs. The clinical trials of LEF in RA patients were started in the mid-1990s. LEF has subsequently been widely used in practical healthcare and proved to be one of the most effective drugs in its family. The international and national recommendations for RA treatment regard it as one of the main components of comprehensive treatment, which can be prescribed at any stage of the disease either as the only BAID or combined with other antirheumatic drugs, including synthetic BAIDs and genetically engineered drugs. |
|---|---|
| ISSN: | 1996-7012 2310-158X |